Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CPN1 | P15169 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961183 | 0.97 | POLB (0.41) | POLBTDP1L3MBTL1SLC6A3TBXAS1 | |
| SCHEMBL29009923 | 0.85 | LMNA (0.46) | POLBTBXA2RPPARDMMEPTGS1 | |
| SCHEMBL27960498 | 0.84 | MME (0.39) | POLBTDP1L3MBTL1TBXAS1TBXA2R | |
| SCHEMBL961245 | 0.84 | POLB (0.50) | POLBTDP1L3MBTL1SLC6A3TBXAS1 | |
| SCHEMBL962850 | 0.84 | TBXAS1 (0.52) | POLBTBXAS1CPN1CPB2HDAC1 | |
| SCHEMBL28987106 | 0.83 | TBXA2R (0.56) | POLBTDP1L3MBTL1TBXAS1TBXA2R | |
| SCHEMBL964027 | 0.83 | CES2 (0.37) | POLBTDP1L3MBTL1SLC6A3TBXAS1 | |
| SCHEMBL27842577 | 0.83 | POLB (0.53) | POLBTDP1L3MBTL1TBXAS1PTGS1 | |
| SCHEMBL2489621 | 0.83 | HTR7 (0.46) | POLBMMEPTGS1PTGS2HDAC3 | |
| SCHEMBL961952 | 0.83 | KMT2A (0.51) | POLBTDP1L3MBTL1TBXAS1CPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111315745-B | Triazolo-aza derivatives | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3728262-B1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-03-15 | — | — | EP | disclosed |
| US-11440915-B2 | Triazolo-azepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3728262-A1 | TRIAZOLO-AZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111315745-A | Triazolo-aza derivatives | 豪夫迈·罗氏有限公司 | 2020-06-19 | — | — | CN | disclosed |
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| CN-102356081-A | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2012-02-15 | — | — | CN | disclosed |
| EP-2379553-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317681-A1 | TRIAZOLO-AZEPINE DERIVATIVES | HUWE1, APP, PSEN1 | POLB 649/4885TDP1 154/4885L3MBTL1 1319/4885 |
| US-11440915-B2 | Triazolo-azepine derivatives | HUWE1, PSEN1, UPF1 | POLB 753/4885TDP1 143/4885L3MBTL1 1175/4885 |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | APP, BACE1, APBA1 | POLB 1116/4885TDP1 1618/4885L3MBTL1 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.